Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

IL28B in the era of direct-acting antivirals for hepatitis C.

Publication ,  Journal Article
Muir, AJ
Published in: J Clin Gastroenterol
March 2013

The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-α and ribavirin. In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-α and ribavirin, and boceprevir and telaprevir attenuate the association between the IL28B genotype and treatment response. Although sustained virologic response rates are improved for all IL28B genotypes with the addition of the protease inhibitors, the unfavorable IL28B genotypes have substantial benefit. IL28B also predicts the likelihood of shortened duration of treatment with the protease inhibitor combination. As hepatitis C treatment moves towards interferon-free regimens, the role of IL28B in these regimens is under investigation.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Gastroenterol

DOI

EISSN

1539-2031

Publication Date

March 2013

Volume

47

Issue

3

Start / End Page

222 / 227

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Proline
  • Oligopeptides
  • Interleukins
  • Interferons
  • Humans
  • Hepatitis C
  • Hepacivirus
  • Genotype
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Muir, A. J. (2013). IL28B in the era of direct-acting antivirals for hepatitis C. J Clin Gastroenterol, 47(3), 222–227. https://doi.org/10.1097/MCG.0b013e3182680221
Muir, Andrew J. “IL28B in the era of direct-acting antivirals for hepatitis C.J Clin Gastroenterol 47, no. 3 (March 2013): 222–27. https://doi.org/10.1097/MCG.0b013e3182680221.
Muir AJ. IL28B in the era of direct-acting antivirals for hepatitis C. J Clin Gastroenterol. 2013 Mar;47(3):222–7.
Muir, Andrew J. “IL28B in the era of direct-acting antivirals for hepatitis C.J Clin Gastroenterol, vol. 47, no. 3, Mar. 2013, pp. 222–27. Pubmed, doi:10.1097/MCG.0b013e3182680221.
Muir AJ. IL28B in the era of direct-acting antivirals for hepatitis C. J Clin Gastroenterol. 2013 Mar;47(3):222–227.

Published In

J Clin Gastroenterol

DOI

EISSN

1539-2031

Publication Date

March 2013

Volume

47

Issue

3

Start / End Page

222 / 227

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Proline
  • Oligopeptides
  • Interleukins
  • Interferons
  • Humans
  • Hepatitis C
  • Hepacivirus
  • Genotype